Compounded GLP-1 in 2026

1. 2024-2026 enforcement timeline

Key events shaping compounded GLP-1 landscape:

• December 2024: FDA resolves tirzepatide shortage. Eli Lilly demands compounding pharmacies cease tirzepatide production. Lawsuits filed.
• February 2025: FDA resolves semaglutide shortage. Mass-compounding legal basis under 503A shortage exemption ends.
• March-June 2025: Compounding industry groups file litigation challenging FDA resolutions. Partial preliminary injunctions in some districts. Patchwork enforcement.
• Mid-2025: FDA issues warning letters to multiple compounding pharmacies. First major enforcement actions.
• Late 2025: Eli Lilly wins several cases against compounded tirzepatide producers. Court-ordered cease + desist for specific companies.
• Early 2026: Hims announces exit from compounded GLP-1 category. Other major telehealth platforms scale back.
• Mid-2026: FDA enforcement actions against 30+ compounding companies cumulative. Patchwork ongoing legal cases.

2. Legal basis narrowed (and what remains)

Pre-2025 mass compounding rested on the FDA shortage list — when a drug is officially "shortage," 503A pharmacies could legally compound versions for the duration. Once FDA declares shortage resolved, that pathway closes.

What remains legally:

• Traditional 503A compounding for individual medical need: Allergy to inactive ingredient, custom dose not commercially available, pediatric/geriatric formulation requirements. Per-patient prescriptions only.
• 503B outsourcing facility production for clinical settings: Hospital, clinic, surgery center supplies. Not retail telehealth.
• State-specific exceptions: Some states allow broader compounding scope; varies by state Board of Pharmacy rules.

What ended:

• Mass compounding under shortage exemption (semaglutide, tirzepatide both resolved)
• Telehealth-platform-direct compounding production at scale
• "Cost reasons" as standalone justification for compounding commercially-available drugs

3. Hims exit — the symbolic moment

Hims (parent: Hims & Hers Health) was one of the largest distributors of compounded semaglutide during 2023-2024, building substantial business around the GLP-1 weight loss boom. In early 2026, Hims announced it would discontinue compounded GLP-1 offerings, citing regulatory uncertainty + business model considerations.

The exit's significance: Hims wasn't a small operation. Its decision signaled that even well-resourced telehealth companies couldn't make compounded GLP-1 economically viable post-shortage-resolution. Other major platforms followed similar contraction patterns.

Hims patients formerly on compounded GLP-1 received transition notices + options:

• Switch to Wegovy via Hims\' FDA-approved partner pharmacies
• Use LillyDirect Zepbound at $349-499/month
• Source compounded from alternative providers (Hims did not directly refer)

4. Remaining compounded options in 2026

The compounded GLP-1 market hasn't disappeared — it contracted and changed shape. Categories of remaining options:

Smaller specialty telehealth platforms

• Mochi — continues compounded with 503A pharmacy partnerships
• Henry Meds — compounded semaglutide focus
• GobyMeds — tiered pricing structure
• Embody — Flat Program ~$150/month
• Lemonaid Health — introductory pricing

Smaller platforms may have less marketing visibility but typically operate within legal compounding pathways. Trade-off: less established, supply may be more variable.

Direct 503A pharmacy relationships

Some patients work directly with established compounding pharmacies bypassing telehealth platforms entirely. Requires: prescriber to write directly to specific compounding pharmacy, often more administrative work, can be cost-effective.

503B outsourcing facilities

FDA-registered facilities продолжают operate under stricter cGMP standards. Less common in retail telehealth, more institutional. Higher quality oversight but typically higher cost than 503A.

5. LillyDirect changed cost calculus

LillyDirect's direct cash-pay Zepbound pricing materially shifted the cost equation. Comparison:

• Pre-LillyDirect (2023): FDA-approved Zepbound ~$1,086/month list. Compounded semaglutide ~$250/month. Spread: 4× difference.
• Post-LillyDirect (2026): Zepbound vials $349-499/month direct. Compounded semaglutide $150-300/month. Spread: 1.5-2× difference.

At 1.5-2× cost difference, many patients now find FDA-approved oversight worth the premium. Particularly considering:

• Zepbound\'s 22.5% average weight loss (vs ~15% for compounded semaglutide)
• Supply continuity (no shortage risk on commercial product)
• Regulatory clarity (FDA-approved finished product)
• Possible insurance coverage (compounded almost never covered)

6. Transition strategy if needed

If you\'re on compounded GLP-1 in 2026 and considering FDA-approved alternative:

1. Identify equivalent molecule: Compounded semaglutide → Wegovy (weight) or Ozempic (diabetes). Compounded tirzepatide → Zepbound (weight) or Mounjaro (diabetes).
2. Time the transition: Schedule first FDA-approved dose ~7 days after last compounded dose (standard weekly cycle, no washout needed since same molecule).
3. Dose mapping: Continue at your established dose if well-tolerated. Some prescribers restart at lower dose if you've been on compounded for <6 months; others maintain current dose if stable.
4. Cost optimization: Check insurance coverage. If commercial with weight indication: explore savings card. If uninsured + want tirzepatide: LillyDirect $349-499. If uninsured + want semaglutide: NovoCare $650 or compounded.
5. Expect minor side-effect reset: Some patients notice mild GI return for 1-2 weeks during switching, even at same dose. Likely due to slight formulation differences (preservatives, carrier vehicles).

7. How to verify compounding pharmacy in 2026

If you proceed with compounded GLP-1, due diligence matters more than ever:

• State license verification: Every state Board of Pharmacy has public license lookup. Search exact pharmacy name + state.
• Sterile compounding certification: Verify pharmacy has sterile compounding certification (separate from standard pharmacy license).
• PCAB accreditation: Voluntary but meaningful quality standard. Look for PCAB seal on pharmacy website or check PCAB directory.
• USP <797> compliance: Ask pharmacy if they self-attest USP <797> compliance. Reputable pharmacies will answer immediately.
• API source disclosure: Ask which supplier they use for semaglutide or tirzepatide API. Reputable pharmacies use FDA-registered suppliers.
• API form verification: Confirm preparation uses "semaglutide" — NOT "semaglutide sodium" or "semaglutide acetate" (salt forms FDA flagged as unapproved).
• Real prescription requirement: Any pharmacy shipping without real prescriber relationship is operating illegally. Avoid.
• Beyond-use date check: Label should specify BUD. Refrigeration usually required.

8. What\'s next 2026-2027

Expected developments via 2027:

• Continued FDA enforcement against compounding violations
• Possible legal clarity on traditional 503A pathway through ongoing litigation
• Further telehealth consolidation toward FDA-approved offerings
• New entrants in FDA-approved cash-pay programs — Novo Nordisk likely expanding direct semaglutide cash-pay options
• Generic semaglutide approaching: Patent expiry in some markets 2026-2031; generic timing uncertain in US but possible major price disruption when it happens
• Pipeline drug approvals may further shift landscape (orforglipron oral tirzepatide, retatrutide triple agonist)

9. FAQs

What happened to compounded GLP-1 in 2026?

The compounded GLP-1 market contracted significantly in 2026 due to converging factors: (1) FDA resolved both semaglutide (Feb 2025) and tirzepatide (Dec 2024) shortages, eliminating the primary legal basis for mass compounding under 503A exemptions; (2) FDA enforcement actions against 30+ compounding companies during 2025-2026 for various violations (mass production, salt-form usage, false marketing); (3) Hims announced exit from compounded GLP-1 in early 2026; (4) Eli Lilly aggressive litigation against compounded tirzepatide. Result: many telehealth platforms ceased compounded GLP-1 for new patients; existing patients increasingly transitioned to FDA-approved alternatives.

Can I still get compounded semaglutide in 2026?

Yes, but options have narrowed substantially. Traditional 503A pharmacies continue serving individual patient prescriptions where medical need is documented. Pricing remains competitive ($150-300/month). Trade-offs versus 2024: fewer providers, more variable quality, regulatory uncertainty, possible supply interruptions. Major remaining providers as of mid-2026: smaller telehealth platforms (Henry Meds, Mochi, GobyMeds for existing patients), direct compounding pharmacies in some states. Always verify pharmacy is state-licensed + PCAB-accredited.

Should I switch from compounded to FDA-approved in 2026?

Strong arguments for switching: (1) LillyDirect Zepbound vials at $349-499/month closed the cost gap significantly — FDA-approved tirzepatide is now competitive with compounded semaglutide pricing; (2) Regulatory clarity — FDA-approved products have full oversight; (3) Supply continuity — compounded supply increasingly precarious; (4) Insurance reimbursement — FDA-approved sometimes covered; compounded almost never. Arguments to stay compounded: cost is the absolute priority + Zepbound LillyDirect pricing still too high; established relationship with trustworthy compounding pharmacy; on a stable regimen with positive outcomes.

What was the Hims compounded GLP-1 exit about?

In early 2026, Hims announced it would stop offering compounded GLP-1 medications, citing regulatory uncertainty + business model considerations. Hims had been one of the largest telehealth distributors of compounded semaglutide during the 2023-2024 shortage era. The exit signaled broader industry contraction. Hims continues offering FDA-approved Wegovy through partner pharmacies. Patients formerly receiving compounded semaglutide via Hims received transition notices and were routed to FDA-approved options or other compounding sources.

What is LillyDirect and how does it relate to compounded?

LillyDirect is Eli Lilly's direct-to-consumer cash-pay program selling Zepbound (FDA-approved tirzepatide) single-dose vials at $349/month (2.5mg) up to $499/month (15mg). It accepts cash-pay only — no insurance billing — but available to anyone in the US with a valid prescription. LillyDirect materially changed the cost-benefit calculation for compounded GLP-1: FDA-approved tirzepatide at $349-499 is now competitive with compounded semaglutide at $150-300, particularly when factoring in regulatory oversight + supply continuity. Many patients formerly on compounded tirzepatide transitioned to LillyDirect Zepbound in 2025-2026.

• Editorial board reviewed
• CC BY 4.0 data
• FDA-source citations
• Affiliate disclosed

Regulatory landscape continues evolving. Always verify current legal + pharmacy status before purchase. Full disclaimer.